Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.

Céline PhanA BeauchetA-C BurztejnM Severino-FreireS BarbarotC GirardA LasekZ ReguiaiS Hadj-RabiaC AbasqE BrenautC DroitcourtM PerrusselS MalletA PhanJean-Philippe LacourA KhemisE BourratG ChabyR DebordeP PlantinA MaruaniM PiramF MaccariA-C FougerousseI Kupfer-BessaguetX BalguérieH BarthelemyL MartinN Quiles-TsimaratosL Mery-BrossardV PallureD Lons-DanicD Bouilly-AuvrayM Beylot-BarryE PuzenatF AubinE Mahénull nullnull null

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2019)

Our real-life comparative study found that ustekinumab had the best drug survival outcome. The profile of SAEs in children was comparable to that in adults. These results will assist dermatologists in the decision-making process when choosing treatment options for children with psoriasis in daily practice.

Keyphrases

primary care
decision making
young adults
healthcare
physical activity
emergency department
atopic dermatitis
quality improvement
free survival
adverse drug
early life
skin cancer